Pasithea Therapeutics Corporation has released a new investor presentation highlighting its pipeline developments. The presentation features PAS-004, described as a next-generation macrocyclic MEK inhibitor designed to address the limitations of earlier generation MEK inhibitors. According to the company, macrocyclic molecules such as PAS-004 typically demonstrate superior target binding, oral bioavailability, potency, and pharmacokinetic properties. The document also outlines ongoing clinical activities, including a Phase 1 trial of PAS-004 in advanced cancer patients. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on November 25, 2025, and is solely responsible for the information contained therein.